Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus on Sodium- Glucose Cotransporter-2 Inhibitors Induced by COVID-19

AlSaraj F, Krishnareddy K, Capatos G and Medhat P

Department of Endocrinology, Mediclinic Parkview Hospital, Dubai, UAE Intensive Care Unit of Mediclinic Parkview Hospital, Dubai, UAE

^*Correspondance to: AlSaraj F 

 PDF  Full Text Case Report | Open Access

Abstract:

A 47-years old lady presented to the emergency department complaining of severe symptoms of lower respiratory tract infection of three days duration. She has history of type 2 diabetes on Dapagliflozin, is one of the sodium- glucose cotransporter-2 inhibitor. Clinical, radiological and laboratory tests confirmed the diagnosis of moderate COVID-19 pneumonia and euglycemic diabetes ketoacidosis. The patient admitted to the intensive care unit for better management and discharged home after nine days of hospitalization. We reporting, COVID-19 could induce this serious metabolic abnormality. Therefore, clinicians should be aware of this complication in this current pandemic.

Keywords:

Cite the Article:

AlSaraj F, Krishnareddy K, Capatos G, Medhat P. Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus on Sodium- Glucose Cotransporter-2 Inhibitors Induced by COVID-19. Ann Clin Case Rep. 2021; 6: 1948..